What is Velpanat and what is it used for? Velpanat (generic Epclusa) is a generic antiviral drug produced by Natco that is used to treat chronic hepatitis C in adults. Velpanat contains active substances and velpatasvir sofosbuvir. How is Velpanat used? Velpanat can only be obtained with a prescription and treatment should be initiated and supervised by a physician experienced in the management of patients with chronic hepatitis C. Velpanat is available as tablets containing 400 mg of sofosbuvir and 100 mg of velpatasvir. Hepatitis C virus exists in several varieties (genotypes), and Velpanat can be used to treat hepatitis C caused by all genotypes of the virus. The recommended dose is one tablet taken once a day for 12 weeks. In patients with decompensated liver disease (when the liver is no longer functioning properly), Velpanat is taken together with another medicine, called ribavirin. Addition of ribavirin to Velpanat treatment may also be considered in patients with compensated liver cirrhosis (liver sclerosis but with proper functioning) and who are infected with hepatitis C virus genotype 3, which is harder to treat. How does Velpanat work? Velpanat active substances, sofosbuvir and velpatasvirul, blocking two proteins essential for replication of hepatitis C virus sofosbuvir block the action of an enzyme called "NS5B RNA-dependent RNA polymerase" and velpatasvirul targets a protein called "NS5A". Blocking these proteins, Velpanat stops multiplication of hepatitis C virus infection of new cells. What is the risk associated with Velpanat? Velpanat is contraindicated in combination with the following medicines, as they may reduce the levels of sofosbuvir and velpatasvir in the blood, and can therefore reduce the efficacy of Velpanat: - rifampicin, rifabutin (antibiotics); - carbamazepine, phenobarbital, phenytoin (medicines to treat epilepsy); - St John's wort (herbal tea used to treat depression and anxiety). For the full list of side effects or restrictions with Velpanat, read the prospectus. The product summary and package leaflet included recommendations and precautions for the safe and effective use of Velpanat, to be followed by healthcare professionals and patients.